The Beneficial Effect Of Renadyl (Kibow) Probiotics On Patients With Chronic Kidney Diseases, With Comparison Between Diabetic And Non Diabetic Patients
Introduction: The aims of this study are to identify the effect of Kibow biotic (K.B. = RenadylTm) probiotic
dietary supplements in decreasing the blood urea and serum creatinine in patients with chronic kidney disease (CKD) stages
3 and 4 and to compare the effect of the (K.B.) on diabetic and non-diabetic CKD patients. Method: This was a prospective,
randomized, double blind, placebo controlled, crossover study of probiotic bacteria dietary supplement (Kibow=KB)
conducted on 25 outpatients with CKD stage 3 and 4. In this studywe divided the patients into two groups: Group A, 11
Diabetic patients, received the probiotic bacteria in the formulation (KB). Group B, 14 non diabetic patients received the
placebo. After 3 months, cross over was made between the two groups. Results: In comparison with the placebo period,
blood urea levels were significantly lower during the KB treatment for both groups. Conclusion: The Renadyl probiotic
dietary supplement is a safe product to be used in our patients with CKD stage 3 and 4 with significant decrease in blood
urea in all the patients. There were no significant changes in serum creatinine in diabetic patients, because of the presence of
neurogenic bladder and long term antibiotics used.
Keywords—Beneficial effect of probiotics, chronic kidney disease.